Media Inquiry Response from Kuros Biosciences
Kuros Biosciences, a frontrunner in pioneering bone healing technologies, has been alerted to inquiries from a notable Dutch financial news outlet regarding the departure of Albert Arp, a former director on the company’s Board. This inquiry coincides with an upcoming publication that may discuss the details surrounding Arp's resignation, specifically an allegation concerning the unauthorized sharing of sensitive pricing information with an entity that does not have ties to Kuros's corporate governance.
Understanding the significance of transparency in such situations, Kuros is actively conducting an internal investigation concerning this allegation. It's crucial to underline that Arp's resignation pertains solely to his personal actions, and it does not reflect upon the strategic decisions, financial performance, or operational integrity of Kuros Biosciences as a whole.
About Kuros Biosciences
Kuros Biosciences is on a dedicated mission to innovate within the realm of biologic technologies. With a presence that spans the United States, Switzerland, and the Netherlands, the company proudly holds a listing on the SIX Swiss Exchange under the ticker SWX:KURN. Kuros's flagship product, MagnetOs™, represents a groundbreaking advancement in bone graft technology and has garnered recognition across multiple continents for its effectiveness in enhancing surgical outcomes.
Innovative Technologies Shaping the Future
MagnetOs™ is designed to instill confidence in surgeons by providing predictable fusion outcomes in bone healing. A clinical study highlighted in Spine illustrated that MagnetOs achieved an impressive fusion rate of 79%, significantly outperforming the 47% rate of traditional autograft methods in posterolateral fusions (PLFs). Notably, among patients who were active smokers, the effectiveness of MagnetOs was even more pronounced, showcasing its potential in diverse patient populations.
Transforming Bone Healing with Advanced Solutions
What sets MagnetOs apart is its unique NeedleGrip™ technology, which promotes bone growth through an innate interaction with the immune system. This innovative approach means that no additional cells or growth factors are needed, making it a safe and efficient option for various surgical procedures. It’s ready-to-use, easy to mold, and remains reliably in place, carrying no intrinsic risk of transferring human tissue-related diseases, and it is FDA-cleared for use across the spine, including interbody procedures.
Company Contact Information
For additional information and inquiries regarding Kuros Biosciences, please reach out to:
**Kuros Biosciences AG**
**Alexandre Müller**
Investor Relations
Tel: +41 43 268 32 31
Email: IR@kurosbio.com
**Daniel Geiger**
Chief Financial Officer
Tel: +41 44 733 47 41
Email: daniel.geiger@kurosbio.com
Frequently Asked Questions
1. What is the reason for Albert Arp's resignation?
Albert Arp's resignation is linked to allegations concerning the unauthorized sharing of sensitive information, though the inquiry pertains to his personal actions and does not affect the company.
2. How does this resignation affect Kuros Biosciences?
Kuros emphasizes that the resignation has no impact on its operational strategies or financial health.
3. What is MagnetOs and its significance?
MagnetOs™ is an advanced bone graft technology effective in promoting fusion outcomes in surgeries, currently utilized worldwide.
4. How does Kuros ensure patient safety with MagnetOs?
MagnetOs is designed to eliminate risks associated with human tissue transmission, being FDA-cleared for various spinal procedures.
5. How can I learn more about Kuros Biosciences?
For further inquiries, potential investors can contact their Investor Relations team or visit kurosbio.com.
